Where does GDTC stock trade?

CytoMed Therapeutics Limited (GDTC) is listed on NASDAQ.

What sector and industry is GDTC in?

CytoMed Therapeutics Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did CytoMed Therapeutics Limited go public?

CytoMed Therapeutics Limited (GDTC) completed its IPO in 2023.

What companies are similar to GDTC?

Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GDTC side-by-side with any of them on Quantisnow.

How can I track GDTC on Quantisnow?

Quantisnow aggregates CytoMed Therapeutics Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GDTC to receive live email and push alerts on every new disclosure.

GDTC

NASDAQ

CytoMed Therapeutics Limited

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2023

$1.05-0.24 (-18.22%)

News25/Ratings0

Price$1.05+0.02 (+2.43%)

2026-03-092026-06-10

News · 26 weeks16-71%

2025-12-142026-06-07

Mix1290d

Insider6(50%)
SEC Filings5(42%)
Other1(8%)

Latest news

25 items

7dSEC
SEC Form 6-K filed by CytoMed Therapeutics Limited
6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
15dINSIDER
New insider Toh Keng Kiat claimed ownership of 4,000 units of Ordinary Shares (SEC Form 3)
3 - CytoMed Therapeutics Ltd (0001873093) (Issuer)
26dINSIDER
New insider Choo Chee Kong claimed ownership of 2,587,746 units of Ordinary Shares (SEC Form 3)
3 - CytoMed Therapeutics Ltd (0001873093) (Issuer)
26dINSIDER
New insider Yew Chak Hua claimed ownership of 2,469 units of Ordinary Shares (SEC Form 3)
3 - CytoMed Therapeutics Ltd (0001873093) (Issuer)
26dINSIDER
SEC Form 3 filed by new insider Leong Mark Kei Wei
3 - CytoMed Therapeutics Ltd (0001873093) (Issuer)
26dINSIDER
New insider Goh Yvonne claimed ownership of 25,781 units of Ordinary Shares (SEC Form 3)
3 - CytoMed Therapeutics Ltd (0001873093) (Issuer)
26dINSIDER
New insider Tan Yoong Ying claimed ownership of 25,781 units of Ordinary Shares (SEC Form 3)
3 - CytoMed Therapeutics Ltd (0001873093) (Issuer)
26dSEC
SEC Form 6-K filed by CytoMed Therapeutics Limited
6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
30dSEC
SEC Form 6-K filed by CytoMed Therapeutics Limited
6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
57dSEC
SEC Form 6-K filed by CytoMed Therapeutics Limited
6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
71dSEC
SEC Form 6-K filed by CytoMed Therapeutics Limited
6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
71dSEC
SEC Form 20-F filed by CytoMed Therapeutics Limited
20-F - CytoMed Therapeutics Ltd (0001873093) (Filer)
133dSEC
SEC Form 6-K filed by CytoMed Therapeutics Limited
6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
133dPR
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today issued a statement to address recent statements containing inaccurate and misleading claims regarding the Company's research programs, clinical progress, and operations. CytoMed categorically rejects such claims which have no basis. Certain statements circulating publicly mis-characterize the Company's scie
148dSEC
SEC Form 6-K filed by CytoMed Therapeutics Limited
6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
148dPR
CytoMed Therapeutics' new year update and seeks shareholders' feedback on proposal to improve shareholder value for their patient capital
SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to update shareholders as we enter a new exciting year in 2026. As mentioned in previous announcements, CytoMed through new subsidiary LongevityBank is also diversifying its product pipeline through the process development of clinical-grade cord blood-derived Natural Killer cells. In so doing, it will
184dSEC
SEC Form 6-K filed by CytoMed Therapeutics Limited
6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
184dPR
CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia
SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today announced that it has entered into a Memorandum of Understanding with Universiti Malaya Medical Centre ("UMMC") a teaching hospital under Universiti Malaya to establish a multi-site, first-in-human Phase I clinical trial to investigate the safety and efficacy of CytoMed's patented allogeneic unmodified Gamma
204dSEC
SEC Form 6-K filed by CytoMed Therapeutics Limited
6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
204dPR
CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary novel technologies to develop affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it has completed with full payment the acquisition of the allogeneic gamma delta T cell technology (termed "TCB-002") of TC BioPharm Limited ("TCBL"), a subsidiary of TC BioPharm (Holdings) PLC (OTC:TCBPY). This follows CytoMed's announcement on October 14, 2025 regarding its proposed acquisition
216dSEC
SEC Form 6-K filed by CytoMed Therapeutics Limited
6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
216dPR
CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy
SINGAPORE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it secures non-dilutive investment for its subsidiary, LongevityBank Pte Ltd ("LongevityBank") from ICH Capital Pte Ltd ("ICH Capital"). Following the announcement dated August 28, 2025, the strategic vision is for LongevityBank to focus on autologous (using one's own blood, cells and/or tissues
231dSEC
SEC Form 6-K filed by CytoMed Therapeutics Limited
6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
231dPR
CytoMed Therapeutics' Chairman Increases Effective Holdings to 21.95%
SINGAPORE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, today announced that its Executive Chairman and substantial shareholder, Mr Peter Choo has increased his shareholding in the Company through recent open-market purchases of 105,824 shares. This is on top of 187,500 shares which he holds personally, bringing his personal stake in CytoMed to 2.50% as of today. In addit
238dPR
Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 15, 2025 /PRNewswire/ -- Eight new oncology approvals between July and September 2025 marked a pivotal quarter for cancer treatment[1], as cellular immunotherapy platforms continue redefining treatment paradigms for hematologic malignancies and expanding into solid tumors[2]. Recent innovations including CAR-NK cells, CAR-Treg cells, and in vivo CAR-T approaches are solving manufacturing challenges[3] while outpatient CAR-T centers now deliver advanced therapies that previously required lengthy hospital stays[4]. Alternative drug delivery methods and targeted therapy approvals for lung cancer, breast ca

GDTC FAQ

5 questions

Where does GDTC stock trade?
CytoMed Therapeutics Limited (GDTC) is listed on NASDAQ.
What sector and industry is GDTC in?
CytoMed Therapeutics Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did CytoMed Therapeutics Limited go public?
CytoMed Therapeutics Limited (GDTC) completed its IPO in 2023.
What companies are similar to GDTC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GDTC side-by-side with any of them on Quantisnow.
How can I track GDTC on Quantisnow?
Quantisnow aggregates CytoMed Therapeutics Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GDTC to receive live email and push alerts on every new disclosure.